Y-mabs resubmits cancer drug for marketing approval in the US
After several years’ delay, Y-mabs has now filed another marketing application for cancer drug candidate with the US health authority after the first was rejected in 2020.
by christian bundgaard, translated by daniel pedersen
Danish-American biotech firm Y-mabs has announced it has resubmitted a Biologics License Application (BLA) for its delayed cancer drug candidate, omburtamab, with the US health authority, according to a company press release on Thursday last week.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
